Shadi Hamoud | Clinical Trials | Excellence in Research Award

Published on by Top Pharmaceutical

Dr. Shadi Hamoud | Clinical Trials | Excellence in Research Award

Rambam health care campus | Israel

Dr. Shadi Hamoud is a distinguished physician, clinical researcher, and academic leader whose career spans internal medicine, cardiovascular research, and translational medicine. Earning his medical degree with honors from the Faculty of Medicine at the Hebrew University in Jerusalem, Dr. Hamoud embarked on a professional journey characterized by clinical excellence, research innovation, and a deep commitment to medical education. Over the years, he has combined patient-centered care with groundbreaking research, focusing on lipoprotein oxidation, atherosclerosis, the role of the enzyme heparanase in kidney injury, fatty liver disease, and cardiovascular disorders, as well as pioneering clinical trials for novel oral anticoagulants, lipid-modifying agents, diabetes treatments, and therapies for emerging infectious diseases such as COVID-19.As Deputy Director of the Department of Internal Medicine E at Rambam Medical Center and Director of the Clinical Research Unit, Dr. Hamoud has overseen numerous national and international clinical studies, collaborating with leading pharmaceutical companies, including Bayer, Pfizer, Novartis, Sanofi, and AstraZeneca. His research portfolio reflects expertise in designing and conducting complex multicenter clinical trials addressing some of the most challenging issues in cardiovascular medicine and metabolic diseases. Additionally, his clinical consultancy roles across multiple departments at Rambam Health Care Campus highlight his interdisciplinary approach to medicine, ensuring that research findings translate effectively into improved patient outcomes.An accomplished educator, Dr. Hamoud has dedicated decades to training the next generation of physicians, serving as a clinical lecturer at the Technion-Israel Institute of Technology and mentoring medical students, interns, and graduate researchers. Under his supervision, numerous MD and basic science theses have been completed, exploring critical areas such as oxidative stress, endothelial dysfunction, liver steatosis, and the molecular pathways of atherosclerosis. His leadership as Program Director for the Internal Medicine Preparatory Course for National Licensing Examinations further reflects his commitment to academic excellence and medical training standards.

Profile: Orcid

Featured Publications

Hamoud, S., Hacker, I., Karram, T., Fokra, A., Kabala, A., & Abassi, Z. (2024). Gender-specific renoprotective pathways in αMUPA transgenic mice subjected to acute kidney injury. International Journal of Molecular Sciences.

Cohen-Segev, R., Nativ, O., Kinaneh, S., Aronson, D., Kabala, A., Hamoud, S., Karram, T., & Abassi, Z. (2023). Effects of angiotensin 1-7 and Mas receptor agonist on renal system in a rat model of heart failure. International Journal of Molecular Sciences.

Kinaneh, S., Hijaze, W., Mansour-Wattad, L., Hammoud, R., Zaidani, H., Kabala, A., & Hamoud, S. (2022). Heparanase inhibition prevents liver steatosis in E₀ mice. Journal of Clinical Medicine.

[Author names not fully provided]. (n.d.). Predictors of survival in subjects treated in the “shock room” of the emergency department in a tertiary medical center.

Albert Eisenbarth | Clinical Trials | Best Scholar Award

Published on by Top Pharmaceutical

Dr. Albert Eisenbarth | Clinical Trials | Best Scholar Award

Entomologe at Bundeswehr Hospital Hamburg | Germany

Dr. Albert Eisenbarth is a biologist specializing in parasitology, vector biology, and emerging infectious diseases. He earned his doctorate at the University of Tübingen, focusing on Onchocerca ochengi and its relevance to river blindness epidemiology. His career spans international research assignments across Africa, Asia, and Europe, contributing to studies on vector-borne diseases, zoonotic pathogens, and host-parasite interactions. Dr. Eisenbarth has worked at prestigious institutions including the Friedrich Loeffler Institute for Animal Health and the University of Tübingen. With over a decade of field and laboratory expertise, his work bridges veterinary medicine, parasitology, and global health, advancing infectious disease control strategies.

Publication Profile 

Scopus

Education 

Dr. Albert Eisenbarth completed his MSc in Parasitology at the Institute of Tropical Medicine, University of Tübingen, where he conducted his thesis on anisakid nematodes in Australian waters. He pursued doctoral studies at the University of Tübingen, earning his Doctor of Biology degree with a thesis on the biology of Onchocerca ochengi and its epidemiological implications for river blindness. His academic training also included international research exchanges at the University of Melbourne, the Royal Melbourne Institute of Technology, the University of Cape Town, and Kasetsart University in Bangkok. His education combines parasitology, vector biology, and tropical infectious disease research.

Experience 

Dr. Albert Eisenbarth has held diverse research and professional roles. He served as a Research Fellow at the Friedrich Loeffler Institute for Animal Health, working on novel and emerging infectious diseases. Previously, he completed his doctoral and postdoctoral research at the University of Tübingen and in Cameroon within the Onchocerciasis Programme. His career includes positions as Clinical Data Manager at Kendle GmbH and scientific assistant roles at the University of Tübingen. He has undertaken extensive international assignments in Mozambique, Mauritania, Cameroon, Thailand, France, Australia, and South Africa. His expertise encompasses parasitology, vector ecology, epidemiology, and zoonotic disease transmission at the human-animal interface.

Awards and Honors 

Dr. Albert Eisenbarth has received multiple awards and grants for his scientific contributions. He co-coordinated major DFG-funded projects investigating zoonotic viral transmission, including Rift Valley Fever and Crimean-Congo Hemorrhagic Fever in Africa. As principal investigator, he secured a RiSC Young Scientist grant for research on genetic susceptibility to tick-borne diseases in African cattle. His international collaborations earned him a South East Asia–European Union NET II Fellowship, supporting One Health research. He has also been recognized with travel grants from the German Society for Parasitology and the Erwin Riesch Foundation. Additionally, he was awarded DAAD fellowships for both MSc and doctoral studies.

Research Focus 

Dr. Albert Eisenbarth research focuses on parasitology, vector-borne diseases, and zoonotic infections affecting both human and animal health. He has conducted extensive work on the epidemiology of Onchocerca volvulus and Onchocerca ochengi, contributing to onchocerciasis control strategies. His studies include the diversity, abundance, and pathogen carriage of hematophagous vectors such as mosquitoes and ticks in Africa. Additionally, he investigates emerging viral diseases, including Rift Valley Fever and Crimean-Congo Hemorrhagic Fever, across the livestock-wildlife-human interface. Through molecular and field-based approaches, his work integrates parasitology, virology, and epidemiology, providing valuable insights for global health, One Health initiatives, and disease elimination programs.

Publication Top Notes

Molecular detection of Leishmania (Sauroleishmania) adleri (Trypanosomatida: Trypanosomatidae) in Sergentomyia sp. sand flies (Diptera: Psychodidae) in Mali and Niger

Mosquito survey in Mauritania: Detection of Rift Valley fever virus and dengue virus and the determination of feeding patterns

Conclusion

Dr. Albert Eisenbarth possesses the academic excellence, research productivity, and global health relevance that make him a strong candidate for the Research for Best Scholar Award. His innovative studies on parasitic and vector-borne diseases, coupled with his ability to secure competitive grants and engage in international collaborations, demonstrate outstanding scholarly merit. With continued expansion into broader leadership and translational activities, he is well-positioned to further influence the fields of parasitology, epidemiology, and infectious disease research. His track record aligns with the award’s goal of recognizing impactful and forward-looking scientific scholarship.